Comparison of safety and efficacy of oral azithromycin-topical adapalene versus oral doxycycline-topical adapalene in the treatment of acne vulgaris and determination of the effects of these treatments on patients' quality of life Akne vulgaris tedavisinde oral azitromisin ile topikal adapalen ve oral doksisiklin ile topikal adapalen etkinliģinin ve güvenirliģ inin karşilaştirilmasi ve bu tedavilerin yaşam kalitesi üzerine etkilerinin ölçülmesi


Kayhan S., Sabuncu I., Saraçoģlu Z. N., KOKU AKSU A. E., Tozun M.

Turkderm Deri Hastaliklari ve Frengi Arsivi, cilt.46, sa.3, ss.151-155, 2012 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 46 Sayı: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.4274/turkderm.70456
  • Dergi Adı: Turkderm Deri Hastaliklari ve Frengi Arsivi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.151-155
  • Anahtar Kelimeler: Acne vulgaris, treatment, quality of life
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Background and Design: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit. Oral antibiotics and topical retinoids are effective in the treatment of acne. Materials and Methods: In this study, 60 patients with moderate acne vulgaris were evaluated; the patients were randomized into two equal groups. The groups were matched with respect to age, gender and clinical severity of acne. The patients in group 1 received oral azithromycin (500 mg daily on 3 consecutive days per week) and the patients in group 2 received doxycycline (100 mg daily) for 12 weeks. Topical adapalene gel was added to the systemic treatment in both groups. Clinical evaluation was performed at baseline and at the end of first, second and third months. Side effects were recorded. Quality of life in patients was measured with Skindex-29 and Acne Quality of Life Scale before treatment and at the end of third month. Results: At the end of the treatment, the patients in the two treatment groups had clinical improvement of more than 50%. Twenty-one patients in the azithromycin-adapalene group and 23 patients in the doxycycline-adapelene group had more than 80% clinical improvement. There was not any statistically significant difference in the clinical efficacy between the two combinations. Both treatment regimens were safe with minimal side effects. There was statistically significant difference in Skindex-29 and Acne Quality of Life Scale scores at baseline and at the end of the treatment (p< 0.05). There was not any statistically significant difference in the mean scale scores of both quality life scales between the two groups (p>0.05). Conclusion: Both treatments were efficient and safe. There was significant improvement in quality of life scale scores in both groups.